Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products

Global Advanced Therapy Medicinal Products Market to Reach US$24.0 Billion by 2030

The global market for Advanced Therapy Medicinal Products estimated at US$10.8 Billion in the year 2023, is expected to reach US$24.0 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2023-2030. Tissue Engineered Products, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$10.0 Billion by the end of the analysis period. Growth in the Cell Therapy segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.8 Billion While China is Forecast to Grow at 10.5% CAGR

The Advanced Therapy Medicinal Products market in the U.S. is estimated at US$4.8 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Global Advanced Therapy Medicinal Products Market - Key Trends & Drivers Summarized

Advanced Therapy Medicinal Products (ATMPs) represent a frontier in medical innovation, encompassing gene therapies, cell therapies, and tissue-engineered products designed to treat, diagnose, or prevent diseases through advanced biological methods. ATMPs offer groundbreaking treatments for conditions that are currently difficult or impossible to treat with conventional medicines, including various cancers, genetic disorders, and degenerative diseases. These therapies work by modifying the genetic makeup of cells, harnessing the body`s own repair mechanisms, or replacing damaged tissues, thus providing highly personalized and potentially curative treatments. The development and approval of ATMPs are subject to stringent regulatory processes, ensuring their safety, efficacy, and quality.

The field of ATMPs has seen rapid advancements due to significant progress in biotechnology and a deeper understanding of genetic and cellular mechanisms. Innovations such as CRISPR-Cas9 gene editing, induced pluripotent stem cells (iPSCs), and advanced tissue scaffolding techniques have expanded the possibilities for developing effective and targeted therapies. The growing number of clinical trials and successful approvals of ATMPs by regulatory bodies such as the FDA and EMA highlight their therapeutic potential and market viability. Collaborations between academic institutions, biotech companies, and pharmaceutical giants are accelerating the development pipeline, bringing more ATMPs closer to commercialization. Additionally, advancements in manufacturing technologies and scalable production processes are making these therapies more accessible and cost-effective.

The growth in the ATMP market is driven by several factors. Firstly, the increasing prevalence of chronic and genetic diseases, which are often inadequately addressed by traditional treatments, is driving demand for innovative therapies like ATMPs. Secondly, significant advancements in biotechnology and genetic engineering are enabling the development of more effective and personalized ATMPs. Thirdly, substantial investments in research and development by biotech firms and pharmaceutical companies are accelerating the discovery and commercialization of new ATMPs. Additionally, the favorable regulatory environment and expedited approval pathways for breakthrough therapies are facilitating faster market entry for ATMPs. Lastly, the growing patient and physician awareness of the benefits of advanced therapies, coupled with the expanding infrastructure for ATMP manufacturing and distribution, are further propelling the market`s growth.

Select Competitors (Total 190 Featured) -

• Bluebird Bio Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• JCR Pharmaceuticals Co. Ltd.
• Kolon TissueGene, Inc.
• MEDIPOST Co., Ltd.
• Novartis AG
• Organogenesis Inc.
• Spark Therapeutics, Inc.
• UniQure N.V.
• Vericel Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.